Searching for Optimal Dose-Volume Constraints to Reduce Rectal Toxicity after Hypofractionated Radiotherapy for Prostate Cancer

被引:9
作者
Faria, S. [1 ]
Joshua, B. [1 ]
Patrocinio, H. [2 ]
Dal Pra, A. [1 ]
Cury, F. [1 ]
Velly, A. M. [3 ]
Souhami, L. [1 ]
机构
[1] Montreal Gen Hosp, Dept Radiat Oncol, Montreal, PQ H3G 1A4, Canada
[2] McGill Univ, Jewish Gen Hosp, Ctr Hlth, Dept Med Phys, Montreal, PQ H3T 1E2, Canada
[3] McGill Univ, Jewish Gen Hosp, Ctr Hlth, Ctr Clin Epidemiol & Community Studies, Montreal, PQ H3T 1E2, Canada
关键词
Dose-volume constraints; DVH; late rectal toxicity; prostate cancer; radiotherapy; CONFORMAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; EXTERNAL-BEAM RADIOTHERAPY; HISTOGRAMS; 3D-CRT; GY; ADENOCARCINOMA; COMPLICATIONS; MULTICENTER; ESCALATION;
D O I
10.1016/j.clon.2010.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims Late rectal toxicity is a major concern for prostate cancer patients treated with radiotherapy Rectal dose volume constraints set as guidelines to reduce its incidence vary among institutions From a group of patients uniformly treated with hypofractionated radiotherapy we correlated the incidence of late rectal toxicity with rectal dose-volume rectal constraints as described in three randomised trials for prostate cancer Materials and methods Favourable-risk prostate cancer patients received a dose of 66 Gy m 22 fractions without hormonal therapy Toxicity was prospectively assessed using Common Toxicity Criteria v3 The whole or part of the rectum and rectal wall were contoured as an organ at risk for all patients The rectal constraints of the RTOG 0126 RTOG 0415 and the PROFIT trials were used to correlate with late rectal toxicity Results The median follow-up time was 58 months Late rectal toxicity was 62 20 and 18% for grades 0 1 and 2/3 respectively No statistically significant correlation was found between late rectal toxicity and the rectal constraints used in the three trials The number of patients violating the recommended constraints was similar for the group with grade 2/3 toxicity and the group without any toxicity Analysis derived from the actual dose-volume histogram dose parameters of this group of patients did not show a relationship between dose to volume of the rectum and late rectal toxicity that could generate a guideline of dose constraints Conclusion For this group of patients despite the use of recognised dose-volume constraint guidelines of three trials we were unable to establish a relationship between these constraints and the late rectal toxicity registered Further studies on the correlation of dosimetric parameters with rectal toxicity particularly for hypofractionated regimens are required Non-dosimetric factors may also be involved in the risk of late rectal toxicity (C) 2010 The Royal College of Radiologists Published by Elsevier Ltd All rights reserved
引用
收藏
页码:810 / 817
页数:8
相关论文
共 41 条
[21]   Phase II trial of hypofractionated image-guided intensitymodulated radiotherapy for localized prostate adenocarcinoma [J].
Martin, Jarad M. ;
Rosewall, Tara ;
Bayley, Andrew ;
Bristow, Robert ;
Chung, Peter ;
Crook, Juanita ;
Gospodarowicz, Mary ;
Mclean, Michael ;
Menard, Cynthia ;
Milosevic, Michael ;
Warde, Padraig ;
Catton, Charles .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04) :1084-1089
[22]   Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406 [J].
Michalski, JM ;
Purdy, JA ;
Winter, K ;
Roach, M ;
Vijayakumar, S ;
Sandler, HM ;
Markoe, AM ;
Ritter, MA ;
Russell, KJ ;
Sailer, S ;
Harms, WB ;
Perez, CA ;
Wilder, RB ;
Hanks, GE ;
Cox, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02) :391-402
[23]   Influence of rectal volume changes during radiotherapy for prostate cancer:: A predictive model for mild-tomoderate late rectal toxicity [J].
Miralbell, R ;
Taussky, D ;
Rinaldi, O ;
Lomax, A ;
Canales, S ;
Escude, L ;
Nouet, P ;
Özsoy, O ;
Rouzaud, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05) :1280-1284
[24]   Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer [J].
Peeters, STH ;
Lebesque, JV ;
Heemsbergen, WD ;
van Putten, WLJ ;
Slot, A ;
Dielwart, MFH ;
Koper, PCM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (04) :1151-1161
[25]   An assessment of PTV margin definitions for patients undergoing conformal 3D external beam radiation therapy for prostate cancer based on an analysis of 10,327 pretreatment daily ultrasound localizations [J].
Poli, M. Esmeralda Ramos ;
Parker, William ;
Patrocinio, Horacio ;
Souhami, Luis ;
Shenouda, George ;
Campos, Leticia Lucente ;
Podgorsak, Ervin B. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (05) :1430-1437
[26]   Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial [J].
Pollack, A ;
Zagars, GK ;
Starkschall, G ;
Antolak, JA ;
Lee, JJ ;
Huang, E ;
von Eschenbach, AC ;
Kuban, DA ;
Rosen, I .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (05) :1097-1105
[27]  
*RAD THER ONC GROU, RTOG 0415 PHAS 3 RAN
[28]  
Radiation Therapy Oncology Group, RTOG 0126 PHAS 3 RAN
[29]   HYPOFRACTIONATED RADIOTHERAPY FOR FAVORABLE RISK PROSTATE CANCER [J].
Rene, Nicholas ;
Faria, Sergio ;
Cury, Fabio ;
David, Marc ;
Duclos, Marie ;
Shenouda, George ;
Souhami, Luis .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (03) :805-810
[30]   Interim report of toxicity from 3D conformal radiation therapy (3Dd-CRT) for prostate cancer on 3DOG/RTOg 9406, level III (79.2 Gy) [J].
Ryu, JK ;
Winter, K ;
Michalski, JM ;
Purdy, JA ;
Markoe, AM ;
Earle, JD ;
Perez, CA ;
Roach, M ;
Sandler, HM ;
Pollack, A ;
Cox, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04) :1036-1046